With the PDUFA date for Cubist Pharmaceuticals Inc.'s potential blockbuster ceftolozane/tazobactam, branded Zerbaxa, just two weeks away, the Lexington, Mass.-based company became the latest target in a hot round of biopharma dealmaking. Read More
SAN FRANCISCO – Data from Bristol-Myers Squibb Co. and Merck & Co. Inc. reported at the 56th Annual American Society of Hematology suggest that their PD-1 immunotherapies, Opdivo (nivolumab) and Keytruda (pembrolizumab) respectively, may prove to be powerful tools against lymphomas. Read More
HONG KONG — The elucidation of the core structure of a secretory channel in the bacterial outer membrane may provide a target for the development of novel antibiotics aimed at attenuating biofilm formation, Chinese scientists report in the Dec. 1, 2014, early online edition of the Proceedings of the National Academy of Sciences. Read More
Spark Therapeutics Inc. got the jump on what one analyst called "a defining year in gene therapy" with a deal that brought $20 million from Pfizer Inc. and includes the potential for as much as $260 million in milestone payments, as the pair strives for new therapies against hemophilia B. Read More
SAN FRANCISCO – More than 20,000 hematology experts converged here over the weekend for the 56th Annual American Society of Hematology meeting to both present and peruse the latest research and patient care strategies to treat blood cancers. Read More
Without commenting on the patent dance laid out in the Biologic Price Competition and Innovation Act (BPCIA), the Federal Circuit made it clear that biosimilar makers can't jump onto the dance floor before the music starts. Read More
Adagene Inc., of Suzhou, China, said it closed an $8 million series A financing with participation from Fidelity Biosciences, Fidelity Asia Growth and Wuxi Venture Fund. Read More
Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said its global oncology business unit, headquartered in Cambridge, Mass., will be called Takeda Oncology. That name will replace the Millennium: The Takeda Oncology Co. brand. Read More
Advaxis Inc., of Princeton, N.J., said the FDA cleared its investigational new drug application to conduct a phase I/II study to evaluate the combination of ADXS-PSA (ADXS31-142) with Keytruda (pembrolizumab, Merck & Co. Inc.) in patients with previously treated, metastatic castration-resistant prostate cancer. Read More
